COVID-19 Antibody Demonstrates Best-in-Class Breadth and Potency Against a Range of Coronaviruses

Adagio Therapeutics, Inc., announced pre-published in vitro and in vivo data demonstrating its lead antibody candidate, ADG2, shows similar or higher potency against SARS-CoV-2 virus compared to monoclonal antibodies (mAbs) in clinical development, while also uniquely offering broad neutralization against a range of sarbecoviruses that pose a threat to humans.

Adagio stated in a press release issued on November 18, 2020, it 'expects its half-life engineered version of ADG2, called ADG20, to enter clinical studies in early 2021.

Laura Walker, Ph.D., chief scientific officer of Adagio, added: “All of the antibodies currently in clinical development trade-off breadth for potency. They either show broad activity against other sarbecoviruses but lack neutralization potency, or they show high neutralization potency against SARS-CoV-2 but lack activity against other coronaviruses. These data suggest that ADG20 holds the promise of being a broadly protective agent against SARS-CoV-2 as well as future SARS-like coronaviruses that are likely to emerge.”